This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. The target population is patients with active psoriatic arthritis. A total of 222 subjects are planned to be included.
Subjects voluntarily take part in the study after being fully informed, sign a written informed consent form (ICF), and agree to follow procedures specified in the study protocol;
Males and females, 18 to 70 years of age, inclusive at the time of signing of ICF;
Have had an psoriatic arthritis of ≥ 3 months in duration prior to signing of ICF;
Have had active arthritis, characterized by at least ≥3 tender joints (68 joint tenderness counts) and ≥3 swollen joints (66 joint swelling counts).
History of infection as defined in the protocol;
Any of the medical diseases or disorders listed in the protocol;
Significant, uncontrolled or unstable disease in any organ.